Published in Proc Natl Acad Sci U S A on January 28, 2005
The N terminus of Saccharomyces cerevisiae Msh6 is an unstructured tether to PCNA. Mol Cell (2007) 1.51
Conformational analysis of processivity clamps in solution demonstrates that tertiary structure does not correlate with protein dynamics. Structure (2014) 1.49
Structural basis for novel interactions between human translesion synthesis polymerases and proliferating cell nuclear antigen. J Biol Chem (2009) 1.48
Structure of an archaeal PCNA1-PCNA2-FEN1 complex: elucidating PCNA subunit and client enzyme specificity. Nucleic Acids Res (2006) 1.28
Structure of the heterotrimeric PCNA from Sulfolobus solfataricus. Acta Crystallogr Sect F Struct Biol Cryst Commun (2006) 1.21
The MutSalpha-proliferating cell nuclear antigen interaction in human DNA mismatch repair. J Biol Chem (2008) 1.15
Identification of small molecule proliferating cell nuclear antigen (PCNA) inhibitor that disrupts interactions with PIP-box proteins and inhibits DNA replication. J Biol Chem (2012) 1.03
Structure of monoubiquitinated PCNA: implications for DNA polymerase switching and Okazaki fragment maturation. Cell Cycle (2012) 1.03
The crystal structure of Haloferax volcanii proliferating cell nuclear antigen reveals unique surface charge characteristics due to halophilic adaptation. BMC Struct Biol (2009) 1.03
Small-molecule targeting of proliferating cell nuclear antigen chromatin association inhibits tumor cell growth. Mol Pharmacol (2012) 1.02
Unraveling the complexity of ubiquitin signaling. ACS Chem Biol (2012) 1.01
Crystal structures of two active proliferating cell nuclear antigens (PCNAs) encoded by Thermococcus kodakaraensis. Proc Natl Acad Sci U S A (2011) 1.00
MutLalpha and proliferating cell nuclear antigen share binding sites on MutSbeta. J Biol Chem (2010) 0.96
Structures of monomeric, dimeric and trimeric PCNA: PCNA-ring assembly and opening. Acta Crystallogr D Biol Crystallogr (2008) 0.95
A functional analysis of PCNA-binding peptides derived from protein sequence, interaction screening and rational design. Oncogene (2006) 0.95
Phosphorylation of PCNA by EGFR inhibits mismatch repair and promotes misincorporation during DNA synthesis. Proc Natl Acad Sci U S A (2015) 0.94
MDM2 protein-mediated ubiquitination of numb protein: identification of a second physiological substrate of MDM2 that employs a dual-site docking mechanism. J Biol Chem (2012) 0.90
Intrinsic flexibility of ubiquitin on proliferating cell nuclear antigen (PCNA) in translesion synthesis. J Biol Chem (2012) 0.90
Reduced stability and increased dynamics in the human proliferating cell nuclear antigen (PCNA) relative to the yeast homolog. PLoS One (2011) 0.89
Solution structure of human growth arrest and DNA damage 45alpha (Gadd45alpha) and its interactions with proliferating cell nuclear antigen (PCNA) and Aurora A kinase. J Biol Chem (2010) 0.86
Structural insights into the adaptation of proliferating cell nuclear antigen (PCNA) from Haloferax volcanii to a high-salt environment. Acta Crystallogr D Biol Crystallogr (2009) 0.85
ATM protein physically and functionally interacts with proliferating cell nuclear antigen to regulate DNA synthesis. J Biol Chem (2012) 0.84
Crystallographic study of G178S mutant of human proliferating cell nuclear antigen. Acta Crystallogr Sect F Struct Biol Cryst Commun (2008) 0.84
A novel cell permeable DNA replication and repair marker. Nucleus (2014) 0.81
Developing peptide-based multivalent antagonists of proliferating cell nuclear antigen and a fluorescence-based PCNA binding assay. Anal Biochem (2012) 0.80
Proliferating cell nuclear antigen (PCNA) interactions in solution studied by NMR. PLoS One (2012) 0.80
Initial crystallographic study of human PCNA in complex with a peptide containing the noncanonical PIP-box sequence of human DNA polymerase iota. Acta Crystallogr Sect F Struct Biol Cryst Commun (2008) 0.79
Crystal structure of the shrimp proliferating cell nuclear antigen: structural complementarity with WSSV DNA polymerase PIP-box. PLoS One (2014) 0.79
Deviating the level of proliferating cell nuclear antigen in Trypanosoma brucei elicits distinct mechanisms for inhibiting proliferation and cell cycle progression. Cell Cycle (2015) 0.78
Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumour agents. Br J Cancer (2013) 0.78
FANCM interacts with PCNA to promote replication traverse of DNA interstrand crosslinks. Nucleic Acids Res (2016) 0.78
Investigation of N-Terminal Phospho-Regulation of Uracil DNA Glycosylase Using Protein Semisynthesis. Biophys J (2017) 0.78
Flexibility of PCNA-protein interface accommodates differential binding partners. PLoS One (2014) 0.77
The biological activity of G-quadruplex DNA binding papaverine-derived ligand in breast cancer cells. Invest New Drugs (2008) 0.77
Streamlined, automated protocols for the production of milligram quantities of untagged recombinant human cyclophilin-A (hCypA) and untagged human proliferating cell nuclear antigen (hPCNA) using AKTAxpress. Protein Expr Purif (2009) 0.77
Characterization of the proliferating cell nuclear antigen of Leishmania donovani clinical isolates and its association with antimony resistance. Antimicrob Agents Chemother (2014) 0.77
A Peptide mimicking a region in proliferating cell nuclear antigen specific to key protein interactions is cytotoxic to breast cancer. Mol Pharmacol (2014) 0.77
Structure of PCNA from Drosophila melanogaster. Acta Crystallogr Sect F Struct Biol Cryst Commun (2013) 0.76
PCNA dependent cellular activities tolerate dramatic perturbations in PCNA client interactions. DNA Repair (Amst) (2016) 0.75
Disentangling polydispersity in the PCNA-p15PAF complex, a disordered, transient and multivalent macromolecular assembly. Nucleic Acids Res (2017) 0.75
Crystallization and X-ray diffraction studies of crustacean proliferating cell nuclear antigen. Acta Crystallogr Sect F Struct Biol Cryst Commun (2012) 0.75
Destabilization of the PCNA trimer mediated by its interaction with the NEIL1 DNA glycosylase. Nucleic Acids Res (2017) 0.75
A site-selective, irreversible inhibitor of the DNA replication auxiliary factor proliferating cell nuclear antigen (PCNA). Bioorg Med Chem (2014) 0.75
Importance of tuberin in carcinogenesis. Oncol Lett (2017) 0.75
Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr (1997) 137.43
Crystal structure of the eukaryotic DNA polymerase processivity factor PCNA. Cell (1994) 6.54
D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell (1992) 5.51
Structure of the C-terminal region of p21(WAF1/CIP1) complexed with human PCNA. Cell (1996) 5.38
The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther (2002) 4.73
The cell-cycle regulated proliferating cell nuclear antigen is required for SV40 DNA replication in vitro. Nature (1987) 4.43
Structural analysis of a eukaryotic sliding DNA clamp-clamp loader complex. Nature (2004) 4.37
Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev (1993) 3.70
The puzzle of PCNA's many partners. Bioessays (2000) 3.54
Structural basis for FEN-1 substrate specificity and PCNA-mediated activation in DNA replication and repair. Cell (2004) 3.33
A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21WAF1 and proliferating cell nuclear antigen. Curr Biol (1995) 2.57
Akt-dependent phosphorylation of p21(Cip1) regulates PCNA binding and proliferation of endothelial cells. Mol Cell Biol (2001) 1.98
Proliferating cell nuclear antigen (PCNA): ringmaster of the genome. Int J Radiat Biol (2001) 1.68
Identification of binding domains on the p21Cip1 cyclin-dependent kinase inhibitor. Oncogene (1995) 1.59
p21 contains independent binding sites for cyclin and cdk2: both sites are required to inhibit cdk2 kinase activity. Oncogene (1996) 1.53
PCNA, a multifunctional ring on DNA. Biochim Biophys Acta (1998) 1.41
Reversible phosphorylation at the C-terminal regulatory domain of p21(Waf1/Cip1) modulates proliferating cell nuclear antigen binding. J Biol Chem (2000) 1.29
Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1. Curr Biol (1997) 1.28
A quantitative study of the in vitro binding of the C-terminal domain of p21 to PCNA: affinity, stoichiometry, and thermodynamics. Biochemistry (2000) 1.20
D-type cyclin-binding regions of proliferating cell nuclear antigen. J Biol Chem (1994) 1.18
Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A. Curr Biol (1996) 1.17
A direct interaction between proliferating cell nuclear antigen (PCNA) and Cdk2 targets PCNA-interacting proteins for phosphorylation. J Biol Chem (2000) 1.11
Involvement of the interaction between p21 and proliferating cell nuclear antigen for the maintenance of G2/M arrest after DNA damage. J Biol Chem (2001) 1.11
Cellular delivery of impermeable effector molecules in the form of conjugates with peptides capable of mediating membrane translocation. Bioconjug Chem (2001) 1.10
Insights into cyclin groove recognition: complex crystal structures and inhibitor design through ligand exchange. Structure (2003) 1.09
Who binds wins: Competition for PCNA rings out cell-cycle changes. Trends Cell Biol (1997) 1.03
Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit. Curr Med Chem Anticancer Agents (2003) 1.03
A 39 amino acid fragment of the cell cycle regulator p21 is sufficient to bind PCNA and partially inhibit DNA replication in vivo. Nucleic Acids Res (1996) 0.99
Highly potent p21(WAF1)-derived peptide inhibitors of CDK-mediated pRb phosphorylation: delineation and structural insight into their interactions with cyclin A. J Pept Res (2002) 0.99
Antisense oligonucleotides to proliferating cell nuclear antigen and Ki-67 inhibit human mesangial cell proliferation. J Am Soc Nephrol (1996) 0.87
Inhibition of gastric cancer cell proliferation by antisense oligonucleotides targeting the messenger RNA encoding proliferating cell nuclear antigen. Br J Cancer (1994) 0.83
Inhibition of rheumatoid synovial fibroblast proliferation by antisense oligonucleotides targeting proliferating cell nuclear antigen messenger RNA. Arthritis Rheum (1997) 0.81
Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry. Nature (2002) 37.66
International network of cancer genome projects. Nature (2010) 20.35
p53 in health and disease. Nat Rev Mol Cell Biol (2007) 11.33
Large-scale mapping of human protein-protein interactions by mass spectrometry. Mol Syst Biol (2007) 8.16
p53 isoforms can regulate p53 transcriptional activity. Genes Dev (2005) 6.76
Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer (2009) 5.12
Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice. Sci Transl Med (2013) 4.62
Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell (2004) 4.46
Proteomic, functional, and domain-based analysis of in vivo 14-3-3 binding proteins involved in cytoskeletal regulation and cellular organization. Curr Biol (2004) 3.45
Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell (2008) 3.38
Insights into antifolate resistance from malarial DHFR-TS structures. Nat Struct Biol (2003) 3.20
p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish. Genes Dev (2009) 2.57
Translating p53 into the clinic. Nat Rev Clin Oncol (2010) 2.55
The role of mutant p53 in human cancer. J Pathol (2010) 2.49
MeCP2 binding to DNA depends upon hydration at methyl-CpG. Mol Cell (2008) 2.48
p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat Cell Biol (2009) 2.46
Loss of function of def selectively up-regulates Delta113p53 expression to arrest expansion growth of digestive organs in zebrafish. Genes Dev (2005) 2.44
Protein recognition of macrocycles: binding of anti-HIV metallocyclams to lysozyme. Proc Natl Acad Sci U S A (2005) 2.31
Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure. Kidney Int (2005) 2.29
Predictive adaptive responses to maternal high-fat diet prevent endothelial dysfunction but not hypertension in adult rat offspring. Circulation (2004) 2.28
The DEAD box protein p68: a novel transcriptional coactivator of the p53 tumour suppressor. EMBO J (2005) 2.12
Transcription - guarding the genome by sensing DNA damage. Nat Rev Cancer (2004) 2.10
The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. EMBO J (2007) 2.07
Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res (2005) 2.06
The pluripotency rheostat Nanog functions as a dimer. Biochem J (2008) 1.97
Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov (2007) 1.92
Cell type-specific responses of human cells to inhibition of replication licensing. Oncogene (2002) 1.91
Molecular architecture of the Mos1 paired-end complex: the structural basis of DNA transposition in a eukaryote. Cell (2009) 1.88
Use of a computerized guideline for glucose regulation in the intensive care unit improved both guideline adherence and glucose regulation. J Am Med Inform Assoc (2004) 1.85
In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer (2002) 1.84
Clinical Practice Guidelines and Recommendations on Peritoneal Dialysis Adequacy 2011. Perit Dial Int (2011) 1.76
Hypophosphorylation of Mdm2 augments p53 stability. Mol Cell Biol (2002) 1.68
Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents. Chem Biol (2010) 1.66
Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy. Cell Cycle (2009) 1.64
Computer-aided detection in the United Kingdom National Breast Screening Programme: prospective study. Radiology (2005) 1.63
Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy. Oncotarget (2010) 1.62
Regulation of p53 by the ubiquitin-conjugating enzymes UbcH5B/C in vivo. J Biol Chem (2004) 1.61
Mechanism of Mos1 transposition: insights from structural analysis. EMBO J (2006) 1.48
Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance. Nat Chem Biol (2006) 1.47
Ubiquitination of HEXIM1 by HDM2. Cell Cycle (2009) 1.46
Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. Trends Pharmacol Sci (2008) 1.46
Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis. EMBO J (2009) 1.45
Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. Clin Cancer Res (2008) 1.44
Suppression of the deubiquitinating enzyme USP5 causes the accumulation of unanchored polyubiquitin and the activation of p53. J Biol Chem (2008) 1.43
A cyclic pentapeptide derived from the second EGF-like domain of Factor VII is an inhibitor of tissue factor dependent coagulation and thrombus formation. Thromb Haemost (2002) 1.43
Extensive DNA mimicry by the ArdA anti-restriction protein and its role in the spread of antibiotic resistance. Nucleic Acids Res (2009) 1.38
Global proteomic assessment of the classical protein-tyrosine phosphatome and "Redoxome". Cell (2011) 1.34
Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors. J Med Chem (2010) 1.32
Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding. J Mol Biol (2005) 1.31
Atomic structure of Mycobacterium tuberculosis CYP121 to 1.06 A reveals novel features of cytochrome P450. J Biol Chem (2002) 1.31
Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-kappaB pathways. Nat Rev Drug Discov (2008) 1.30
p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients. Breast Cancer Res (2011) 1.29
Nutlin-3 inhibits the NFkappaB pathway in a p53-dependent manner: implications in lung cancer therapy. Cell Cycle (2007) 1.28
Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome. Oncotarget (2011) 1.27
Reactivation of p53: from peptides to small molecules. Trends Pharmacol Sci (2010) 1.25
Molecular simulations of protein dynamics: new windows on mechanisms in biology. EMBO Rep (2008) 1.25
Crystal structure of dihydrofolate reductase from Plasmodium vivax: pyrimethamine displacement linked with mutation-induced resistance. Proc Natl Acad Sci U S A (2005) 1.22
HEXIM1 and the control of transcription elongation: from cancer and inflammation to AIDS and cardiac hypertrophy. Cell Cycle (2007) 1.22
p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes. J Clin Invest (2013) 1.21
Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial. J Thorac Oncol (2013) 1.17
Small-molecule inhibitors of MDM2 as new anticancer therapeutics. Semin Cancer Biol (2009) 1.17
Multiple peptide conformations give rise to similar binding affinities: molecular simulations of p53-MDM2. J Am Chem Soc (2008) 1.16
S-nitrosylation of AtSABP3 antagonizes the expression of plant immunity. J Biol Chem (2008) 1.16
Positive feedback between p53 and TRF2 during telomere-damage signalling and cellular senescence. Nat Cell Biol (2010) 1.14
Dietary soy isoflavone induced increases in antioxidant and eNOS gene expression lead to improved endothelial function and reduced blood pressure in vivo. FASEB J (2005) 1.14
Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J Med Chem (2009) 1.14
Stapled peptides with improved potency and specificity that activate p53. ACS Chem Biol (2012) 1.14
A structure-based mutational analysis of cyclophilin 40 identifies key residues in the core tetratricopeptide repeat domain that mediate binding to Hsp90. J Biol Chem (2002) 1.13
Characterization, crystallization and preliminary X-ray analysis of bifunctional dihydrofolate reductase-thymidylate synthase from Plasmodium falciparum. Acta Crystallogr D Biol Crystallogr (2004) 1.13
Small-molecule inhibitors of the p53 suppressor HDM2: have protein-protein interactions come of age as drug targets? Trends Pharmacol Sci (2004) 1.13
Visuomotor priming by pictures of hand postures: perspective matters. Neuropsychologia (2003) 1.12
In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin Cancer Res (2005) 1.11
Progress in the discovery of polo-like kinase inhibitors. Curr Top Med Chem (2005) 1.11
P14ARF promotes accumulation of SUMO-1 conjugated (H)Mdm2. FEBS Lett (2002) 1.10
Octaheme tetrathionate reductase is a respiratory enzyme with novel heme ligation. Nat Struct Mol Biol (2004) 1.10
M2 pyruvate kinase provides a mechanism for nutrient sensing and regulation of cell proliferation. Proc Natl Acad Sci U S A (2013) 1.10
Insights into cyclin groove recognition: complex crystal structures and inhibitor design through ligand exchange. Structure (2003) 1.09
Effect of high-dose intravenous vitamin C on inflammation in cancer patients. J Transl Med (2012) 1.09
Differential binding of p53 and nutlin to MDM2 and MDMX: computational studies. Cell Cycle (2010) 1.09
A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci J (2005) 1.08
Multi-intervention management of calciphylaxis: a report of 7 cases. Am J Kidney Dis (2011) 1.08
p14 Arf promotes small ubiquitin-like modifier conjugation of Werners helicase. J Biol Chem (2004) 1.07